Non–Small Cell Lung Cancer, Version 6.2015

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873

18F-FAPI PET/CT performs better in evaluating mediastinal and hilar lymph nodes in patients with lung cancer: comparison with 18F-FDG PET/CT

Sun, Y., Sun, Y., Li, Z., Song, S., Wu, K., Mao, J., & Cheng, J. (2024) · European journal of medical research · doi:10.1186/s40001-023-01494-9 · Cited by 18

Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells

Tan, S. J., Yeo, T., Sukhatme, S. A., Kong, S. L., Lim, W., & Lim, C. T. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55947-6_14 · Cited by 18

Adoption of Stereotactic Body Radiotherapy for Stage IA Non–Small Cell Lung Cancer Across the United States

Holmes, J. A., Zagar, T. M., & Chen, R. C. (2017) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkx003 · Cited by 18

MNX1‐AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma

Yang, R., Wang, L., & Han, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27996 · Cited by 18

Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells

Hung, J., Kao, Y.-S., Huang, C.-H., & Hsu, W. (2019) · Scientific Reports · doi:10.1038/s41598-019-39545-z · Cited by 18

Long Noncoding RNA RAET1K Enhances CCNE1 Expression and Cell Cycle Arrest of Lung Adenocarcinoma Cell by Sponging miRNA-135a-5p

Zheng, C. J., Li, X., Ren, Y., Yin, Z., & Zhou, B. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01348 · Cited by 18

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

Thi, A. M., Tin, S. T., McKeage, M. J., & Elwood, M. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00718-w · Cited by 18

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients

Shen, H., Cao, Y., Li, X., Tan, Y., Chen, J., Yang, Z., Kong, Y., & Yuan, Y. (2016) · Medicine · doi:10.1097/md.0000000000003800 · Cited by 18

ATG7 promotes the tumorigenesis of lung cancer but might be dispensable for prognosis predication: a clinicopathologic study

Xie, C., Sun, S., Wang, Z., Tang, F., Hu, P., Yang, Z., Xue, C. H., Gong, J., & Liu, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s107876 · Cited by 18

ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways

Li, K., Quan, L., Huang, F., Li, Y., & Shen, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110580 · Cited by 17

Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer

Jiang, L., Jiang, S., Lin, Y., Yang, H., Xie, Z., Lin, Y., & Long, H. (2015) · Medicine · doi:10.1097/md.0000000000002054 · Cited by 17

Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes

Haque, W. M., Verma, V., Butler, E. B., & Teh, B. S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.003 · Cited by 17

Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China

Li, X., Abbas, M., Li, Y., Teng, Y., Fang, Y., Yu, S., Wen, Y., Wang, L., & Shi, M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.02.004 · Cited by 17

ACY1 regulating PTEN/PI3K/AKT signaling in the promotion of non-small cell lung cancer progression

Chen, H., Wang, W., Xiao, C., Xia, D., Li, F., & Liu, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3127 · Cited by 17

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer

Ahmad, U., Crabtree, T. D., Patel, A. P., Morgensztern, D., Robinson, C. G., Krupnick, A. S., Kreisel, D., Jones, D. R., Patterson, G. A., Meyers, B. F., et al. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.01.069 · Cited by 17

Treatment of Stage IIIA Non–Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist

Santana-Dávila, R., & Martins, R. G. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.013052 · Cited by 18

Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma

Matsumura, Y., Suzuki, H. Y., Ohira, T., Shiono, S., Abe, J., Sagawa, M., Sakurada, A., Katahira, M., Machida, Y., Takahashi, S., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.09.003 · Cited by 16

Nomogram using intratumoral and peritumoral radiomics for the preoperative prediction of visceral pleural invasion in clinical stage IA lung adenocarcinoma

Wang, Y., Lyu, D., Hu, S., Ma, Y., Duan, S., Geng, Y., Zhou, T., Tu, W., Xiao, Y., Fan, L., et al. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-02807-7 · Cited by 16

Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients

Zhang, Y., Zhao, Y., Sun, S., Liu, Z., Zhang, Y., & Jiao, S. (2016) · Tumor Biology · doi:10.1007/s13277-015-4662-x · Cited by 16

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

Wang, L., Cui, J., Guo, A.-X., & Yin, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s136579 · Cited by 16

Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris

Leclère, J.-B., Fournel, L., Etienne, H., Zreibi, C. A., Onorati, I., Roussel, A., Castier, Y., Martinod, E., Pimpec‐Barthes, F. L., Alifano, M., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.08.007 · Cited by 16

Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells

Fei, H., Tian, H., Zhou, X., Yang, M., Sun, B., Yang, X., Jiao, P., & Wang, F.-Z. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.06.023 · Cited by 17

Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand

McKeage, M. J., Tin, S. T., Khwaounjoo, P., Sheath, K. L., Dixon‐McIver, A., Ng, D., Sullivan, R., Cameron, L., Shepherd, P., Laking, G. R., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14435 · Cited by 16

The roles of MASPIN expression and subcellular localization in non-small cell lung cancer

Wang, X.-F., Liang, B., Zeng, D., Lei, W., Cheng, C., Chen, Y., Huang, J., Gu, N., & Zhu, Y. (2020) · Bioscience Reports · doi:10.1042/bsr20200743 · Cited by 16

Treatment Costs of Early-Stage Lung Cancers Detected by Low-Dose Computed Tomography Screening

Verma, V., & Zhen, W. K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.03.036 · Cited by 15

Clinical Significance of a Circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma

Ren, L., Zhong, X., Liu, W., Xu, D., Lei, Y., Zhou, J., Jiang, W., He, Q., Sun, Y., & Ke, Z. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004780 · Cited by 15

Real-World Characteristics and Outcomes of Advanced Non-Small-Cell Lung Cancer Patients with EGFR Exon 19 Deletions or Exon 21 Mutations

Winfree, K. B., Molife, C., Peterson, P. M., Chen, Y., Visseren‐Grul, C., Leusch, M. S., Beyrer, J. K., & Dimou, A. (2021) · Future Oncology · doi:10.2217/fon-2021-0218 · Cited by 17

Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.

Rusthoven, C. G., Kavanagh, B. D., & Karam, S. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.06.15 · Cited by 15

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients

Liu, D., Xu, W., Ding, X., Yang, Y., Su, B., & Fei, K. (2017) · Journal of Cancer · doi:10.7150/jca.21151 · Cited by 15

18 F-Fluoro-2-Deoxy- d -Glucose PET/Computed Tomography Evaluation of Lung Cancer in Populations with High Prevalence of Tuberculosis and Other Granulomatous Disease

Niyonkuru, A., Bakari, K. H., & Lan, X. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.08.003 · Cited by 17

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report

Wang, Y., Liu, S., Wei, X., Yan, B., Li, J., Su, Z., Liu, A., & Zhang, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164968 · Cited by 15

Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

Trosman, J. R., Douglas, M. P., Liang, S., Weldon, C. B., Kurian, A. W., Kelley, R. K., & Phillips, K. A. (2020) · Value in Health · doi:10.1016/j.jval.2020.01.018 · Cited by 15

Reminiscence therapy‐based care program relieves anxiety, depression, and improves quality of life in post‐operational non‐small cell lung cancer patients

Liu, M.-F., & Li, Y. (2021) · Clinical Respiratory Journal · doi:10.1111/crj.13323 · Cited by 15

Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective

Subramanian, J., & Tawfik, O. W. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1924683 · Cited by 15

Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies

Langer, C. J., Paz-Ares, L. G., Wozniak, A. J., Gridelli, C., de Marinis, F., Pujol, J.-L., Antonio, B. S., Chen, J., Liu, J., Oton, A. B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.003 · Cited by 15

EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand

McKeage, M. J., Elwood, M., Tin, S. T., Khwaounjoo, P., Aye, P. S., Li, A., Sheath, K. L., Shepherd, P., Laking, G. R., Kingston, N. J., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0515-4 · Cited by 16

The utility of endosonography for mediastinal staging of non-small cell lung cancer in patients with radiological N0 disease

Shin, S. H., Jeong, B., Jhun, B. W., Yoo, H., Lee, K., Kim, H., Kwon, O. J., Han, J., Kim, J., Lee, K. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.021 · Cited by 15

Regulation of extracellular and intracellular prolactin on cell proliferation and survival rate through GHR/JAK2/STAT3 pathway in NSCLC

Chou, J., Lieu, F.-K., Ho, D. M.-T., Shen, H.-Y., Lin, P.-H., Hu, S., Wang, S., Lin, H., & Wang, P. S. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.128604 · Cited by 14

Precision diagnostics: integration of tissue pathology and genomics in cancer

Sharma, S., George, P. M., & Waddell, N. (2021) · Pathology · doi:10.1016/j.pathol.2021.08.003 · Cited by 16

Cancer Signature Investigation:ERBB2(HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary

Shih, J., Bashir, B., Gustafson, K. S., Andrake, M., Dunbrack, R. L., Goldstein, L. J., & Boumber, Y. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0115 · Cited by 14

Genomics-Enabled Precision Medicine for Cancer

Roos, A., & Byron, S. A. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_5 · Cited by 14

DDX49 is a novel biomarker and therapeutic target for lung cancer metastases

Lian, X., Xiang, D., Peng, C., Chen, J., Liao, M., Sun, G., & Zhang, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14734 · Cited by 14

Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?

Tajarernmuang, P., Ofiara, L., Beaudoin, S., & Gonzalez, A. V. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-4119 · Cited by 14

Circulating microRNA-145 as a diagnostic biomarker for non-small-cell lung cancer: A systemic review and meta-analysis

Tao, S., Ju, X., Zhou, H., & Zeng, Q. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820967124 · Cited by 15

Long non-coding RNA DLX6-AS1 knockdown suppresses the tumorigenesis and progression of non-small cell lung cancer through microRNA-16-5p/BMI1 axis

Wu, C., Lin, W. Z., & Fu, F. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1240 · Cited by 14

Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients

Zhao, T., Gao, Z., Wu, W., He, W., & Yang, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4190 · Cited by 14

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics

Itchins, M., Clarke, S. J., & Pavlakis, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.01.06 · Cited by 13

Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer

Hua, S., Sun, Y., Li, D., Lv, X., Han, J., Xu, F., & Li, X.-D. (2015) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.172980 · Cited by 14

Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective

Rocco, G., Nason, K. S., Brunelli, A., Varela, G., Waddell, T. K., & Jones, D. R. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw040 · Cited by 14

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features

Yang, N., Yue, H., Zhang, B., Chen, J., Chu, Q., Wang, J., Yu, X., Jian, L., Bin, Y., Liu, S., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15052 · Cited by 12

Endobronchial ultrasound elastography: a new method in endobronchial ultrasound-guided transbronchial needle aspiration.

Jiang, J., Turner, J. F., & Huang, J. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.12.53 · Cited by 13

Computed tomography-guided core needle biopsy for lung nodules: low-dose versus standard-dose protocols.

Huang, Y., Cheng, H., & Li, G. (2021) · Videosurgery and Other Miniinvasive Techniques · doi:10.5114/wiitm.2021.103303 · Cited by 13

Optical coherence tomography for identification of malignant pulmonary nodules based on random forest machine learning algorithm

Ding, M., Pan, S.-Y., Huang, J., Yuan, C., Zhang, Q., Zhu, X., & Cai, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260600 · Cited by 13

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date

Chen, H., & Vachhani, P. J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s97746 · Cited by 13

Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials

Wang, Q., Huang, H., Zeng, X., Ma, Y., Zhao, X., & Huang, M. (2016) · PeerJ · doi:10.7717/peerj.2550 · Cited by 14

Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy

Chiang, C., Wang, L., Ho, H., Tsai, C., Yeh, Y., Hsu, W., Chou, T., Chiu, C., & Wu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23686 · Cited by 13

Circular RNA ATXN7 is upregulated in non‑small cell lung cancer and promotes disease progression

Huang, Q., Wang, S., Li, X., Yang, F., Feng, C., Zhong, K., Qiu, M., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10168 · Cited by 13

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

Wang, S., Liang, Q., Chi, Y., Zhuo, M., An, T., Duan, J., Wang, Z., Wang, Y., Zhong, J., Yang, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13356 · Cited by 12

Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States - retrospective real world data

Allen, T. C., Xiao, Y., Yang, B., Croix, D., Abraham, A., Redpath, S., Engstrom-Melynk, J., Shah, R. A., Madala, J., & Bernicker, E. (2021) · Oncotarget · doi:10.18632/oncotarget.28114 · Cited by 12

Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non–Small-Cell Lung Cancer

Kim, I.-H., Lee, I. H., Lee, J. E., Hong, S. H., Kim, T. J., Lee, K. Y., Kim, Y. K., Kim, S. J., Sung, S. W., Park, J. K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.005 · Cited by 12

Value-Based Care in Lung Cancer

Eaton, K. D., Jagels, B., & Martins, R. G. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0116 · Cited by 12

PP7080 expedites the proliferation and migration of lung adenocarcinoma cells via sponging miR‐670‐3p and regulating UHRF1BP1

Dan, W., Shi, L., Wang, L., Wu, D., Huang, X., & Zhong, Y. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3341 · Cited by 12

Hsa_circ_0046263 Drives the Carcinogenesis and Metastasis of Non-Small Cell Lung Cancer Through the Promotion of NOVA2 by Absorbing Mir-940 as a Molecular Sponge

Li, G., Zhao, C., Zhang, H., Yu, J., Sun, Y., & Zhang, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s272603 · Cited by 12

Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease

Ramadan, S., Quan, K., Schnarr, K. L., Juergens, R. A., Hotte, S. J., Mukherjee, S. D., Kapoor, A., Meyers, B. M., & Swaminath, A. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2063067 · Cited by 11

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer

Zaarour, M., Weerasinghe, C. K., Nazha, B., Hassan, S., & Atallah, J. P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1092385 · Cited by 11

Prognostic significance of centrosomal protein 55 in stage I pulmonary adenocarcinoma after radical resection

Jiang, W., Wang, Z., Chen, G., & Jia, Y. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12330 · Cited by 11

Programmed death‐ligand 1 immunohistochemistry testing for non‐small cell lung cancer in practice

Mino-Kenudson, M. A. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21873 · Cited by 11

Prognostic significance of basal versus superior segment in patients with completely resected lung adenocarcinoma in the lower lobe

Lin, Y., Hung, J., Yeh, Y., & Hsu, W. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12957 · Cited by 11

Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study

Wang, L., Jia, K., Li, F., Zhang, C., Feng, G. L., & Du, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719802 · Cited by 11

The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer

Tanvetyanon, T., Creelan, B., & Antonia, S. J. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1220836 · Cited by 11

Predictors for hilar/intrapulmonary lymph node metastasis in discrete type of clinical N1 non-small cell lung cancer

Fukui, T., Kato, K., Okasaka, T., Kawaguchi, K., Fukumoto, K., Nakamura, S., Hakiri, S., Ozeki, N., & Yokoi, K. (2017) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-017-0827-4 · Cited by 11

Prognosis of limited resection versus lobectomy in elderly patients with invasive lung adenocarcinoma with tumor size less than or equal to 2 cm

Chen, T., Luo, J., Wang, R., Gu, H., Gu, Y., Huang, Q., Wang, Y., Zheng, J., Yang, Y., & Zhao, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.47 · Cited by 11

Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients

Batra, U., Lokeshwar, N., Gupta, S. K., & Shirsath, P. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_532_17 · Cited by 10

Aberrant expression of HIF3A in plasma of patients with non‐small cell lung cancer and its clinical significance

Wei, L., Yuan, N., Chen, Y., & Gong, P. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23889 · Cited by 10

Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

Zhang, M., Guo, H., Zhao, S., Wang, Y., Yang, M., Yu, J., Yan, Y., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9503 · Cited by 10

Retrospective study on video-assisted vs. open mediastinal lymphadenectomy for non-small cell lung cancer: a propensity-matched analysis

Zhang, J., Wu, Y., Li, H., Shen, Q., Yu, C., & Chai, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.64 · Cited by 10

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia

Loong, H. H.-F., Raymond, V. M., Shiotsu, Y., Chua, D. T. T., Teo, P. M. L., Yung, T., Skrzypczak, S. M., Lanman, R. B., & Mok, T. S. K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.022 · Cited by 10

Les tumeurs thoraciques SMARCA4 déficientes : une nouvelle entité

Decroix, E., Leroy, K., Wislez, M., Fournel, L., Alifano, M., Damotte, D., & Mansuet‐Lupo, A. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.12.001 · Cited by 10

Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer

Koshy, M., Malik, R., Mahmood, U. X., Rusthoven, C. G., & Sher, D. J. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.07.009 · Cited by 10

GATA-6 transcriptionally inhibits Shh to repress cell proliferation and migration in lung squamous cell carcinoma

Xu, L., Deng, S., Xiong, H., Shi, W., Luo, S., & Chen, L. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105591 · Cited by 11

T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors

Wulandari, L., Merinda, V., & Soegiarto, G. (2019) · Lung India · doi:10.4103/lungindia.lungindia_182_19 · Cited by 10

M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2-activated ZBTB4 expression

Guan, B., Dai, X., Zhu, Y. M., & Geng, Q. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001414 · Cited by 9

Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights

Bruycker, A. D., Schneiders, F. L., Gulstene, S., Moghanaki, D. M., Louie, A., Palma, D. A., & Senan, S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107848 · Cited by 9

Epigenetic changes driven by environmental pollutants in lung carcinogenesis: a comprehensive review

Zhang, A., Luo, X., Li, Y., Yan, L., Lai, X., Yang, Q., Zhao, Z., Huang, G., Li, Z., Wu, Q., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1420933 · Cited by 11

Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials

Qiao, L., Wang, J., Long, G., & Jiang, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s128187 · Cited by 9

Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma

Meng, X., Song, W., Zhou, B., Liang, M., & Gao, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05390-x · Cited by 10

IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells

Wang, H., Tang, H., Yuan, S., Liang, C., Li, Y., Zhu, S., & Chen, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299028 · Cited by 9

Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung

Binkley, M. S., King, M. T., Shrager, J. B., Bush, K. K., Chaudhuri, A. A., Popat, R. A., Gensheimer, M. F., Maxim, P. G., Guo, H. H., Diehn, M., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.03.021 · Cited by 9

Factors Associated With Treatment of Clinical Stage I Non–Small-cell Lung Cancer: A Population-based Analysis

Berry, M. F., Canchola, A. J., Gensheimer, M. F., Gomez, S. L., & Cheng, I. C. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.009 · Cited by 9

Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer

Haque, W. M., Verma, V., Butler, E. B., Teh, B. S., & Rusthoven, C. G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.026 · Cited by 9

Genetic mutations in lung enteric adenocarcinoma identified using next-generation sequencing.

Li, L., Zhuang, W., Wang, W., Xu, C., Chen, R., Guan, Y., Yi, X., Shao, Y., Tai, Y., Chen, Y., et al. (2017) · PubMed Central · Cited by 9

A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma

Hou, C., Wu, X., Li, C., Wang, C., Liu, J., & Luo, Q. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2022.8481 · Cited by 9

A Deep Learning Approach for Prognostic Evaluation of Lung Adenocarcinoma Based on Cuproptosis-Related Genes

Liang, P., Chen, J., Yao, L., Hao, Z., & Chang, Q. (2023) · Biomedicines · doi:10.3390/biomedicines11051479 · Cited by 9

Patterns of Failure After Surgery for Non–Small-cell Lung Cancer Invading the Chest Wall

Tandberg, D. J., Kelsey, C. R., D’Amico, T. A., Crawford, J., Chino, J., Tong, B. C., Ready, N., & Wright, A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.008 · Cited by 9

Clinical validity of 25-gauge endobronchial ultrasound-guided transbronchial needle in lymph node staging of lung cancer

Okubo, Y., Matsumoto, Y., Tanaka, M., Imabayashi, T., Uezono, Y., WATANABE, S.-I. I., & Tsuchida, T. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3383 · Cited by 9

Clinical Application of Liquid Biopsies

Williams, P. M., & Conley, B. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0240 · Cited by 9

PRRX2 predicts poor survival prognosis, and promotes malignant phenotype of lung adenocarcinoma via transcriptional activates PSMD1

Liu, L., Liu, A., & Liu, X. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101586 · Cited by 8

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer

Pal, S. K., Agarwal, N., Boorjian, S. A., Hahn, N. M., Siefker-Radtke, A. O., Clark, P. E., & Plimack, E. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1429 · Cited by 8

Clinical target volume automatic segmentation based on lymph node stations for lung cancer with bulky lump lymph nodes

Shen, J., Zhang, F., Di, M., Shen, J., Wang, S., Chen, Q., Chen, Y., Liu, Z., Lian, X., Ma, J., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14638 · Cited by 8

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Aisner, D. L., & Riely, G. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5020 · Cited by 39

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Vigneswaran, J., Tan, Y. C., Murgu, S. D., Won, B. M., Patton, K. A., Villaflor, V. M., Hoffman, P. C., Hensing, T. A., Hogarth, D. K., Malik, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7739 · Cited by 27

How and when to use genetic markers for nonsmall cell lung cancer

Lazarus, D. R., & Ost, D. E. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328362075c · Cited by 17

Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer

Mino-Kenudson, M. A., & Mark, E. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0029-rai.1 · Cited by 33